This is a Phase 3 multicenter trial in 2 parts to evaluate the long-term safety and efficacy of navenibart in adult and adolescent participants with hereditary angioedema (HAE) who participated in STAR-0215-301 (NCT06842823; ALPHA-ORBIT). Part 1 provides all participants with navenibart in a dose-controlled fashion; Part 2 introduces a personalized dosing option (PDO) for participants based on individual needs.

开始日期2025-10-01

申办/合作机构

Astria Therapeutics, Inc.

NCT06842823

/ Recruiting临床3期

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)

This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.

开始日期2025-03-20

申办/合作机构

Astria Therapeutics, Inc.

NCT06007677

/ Active, not recruiting临床2期

A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

开始日期2023-09-26

申办/合作机构

Astria Therapeutics, Inc.

100 项与 Navenibart 相关的临床结果

登录后查看更多信息

100 项与 Navenibart 相关的转化医学

登录后查看更多信息

100 项与 Navenibart 相关的专利（医药）

登录后查看更多信息

项与 Navenibart 相关的文献（医药）

2025-07-01·ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults

Article

作者: Morabito, Christopher ; Cohen, Theodora ; Lumry, William ; Gunsior, Michele ; Gustafson, Pamela ; Bernard, Kristine ; Chung, Jou-Ku

BACKGROUND:

Hereditary angioedema (HAE) is a rare, autosomal-dominant disorder characterized by bradykinin-mediated episodic, localized swelling that can be fatal. Currently approved long-term prophylactic therapies for HAE attacks incur substantial treatment burden through frequent dosing. Navenibart (STAR-0215) is a monoclonal antibody inhibitor of plasma kallikrein modified to extend circulating half-life and is under investigation for HAE prophylaxis.

OBJECTIVE:

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of navenibart in healthy adults and to assess the feasibility of every 3- and 6-month dosing.

METHODS:

In this phase 1a study, participants were randomized 3:1 to receive placebo or navenibart in escalating (100-1200 mg) dosing cohorts. Safety outcomes, including treatment-emergent adverse events (TEAEs) and serious AEs, were monitored until the end of the study (day 224). Additional end points included pharmacokinetic parameters and inhibition of plasma kallikrein activity.

RESULTS:

In total, 31 participants received navenibart and 10 received placebo. The median age of the participants was 36 years; 53.7% were male; 51.2% were Black or African American. Rates of TEAEs were similar between navenibart and placebo, and no serious AEs were reported. Navenibart-related TEAEs included injection site reactions, inclusive of erythema, pruritus, and swelling, which resolved without intervention. For all doses more than or equal to 300 mg, navenibart mean half-life ranged from 82 to 105 days and inhibition of factor XIIa-induced plasma kallikrein activity vs placebo was statistically significant (P < .05). Statistically significant inhibition of factor XIIa-induced plasma kallikrein activity vs placebo (P < .05) was observed with all doses of navenibart.

CONCLUSION:

In this first-in-human study, up to 1200 mg of navenibart was well tolerated and demonstrated an extended half-life with durable plasma kallikrein inhibition.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT05477160.

2023-11-01·The Journal of pharmacology and experimental therapeutics

STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema

Article

作者: Bista, Pradeep ; Chandran, Sachin ; Kiselak, Tomas ; Omer, Charles ; Dagher, Rafif ; Fuller, James ; Bedian, Vahe ; Violin, Jonathan ; Chung, Jou-Ku ; Nichols, Andrew ; Harwin, Peter ; Biris, Nikolaos

Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by a deficiency in functional C1 esterase inhibitor, a serpin family protein that blocks the activity of plasma kallikrein. Insufficient inhibition of plasma kallikrein results in the overproduction of bradykinin, a vasoactive inflammatory mediator that produces both pain and unpredictable swelling during HAE attacks, with potentially life-threatening consequences. We describe the generation of STAR-0215, a humanized IgG1 antibody with a long circulating half-life (t_1/2) that potently inhibits plasma kallikrein activity, with a >1000-fold lower affinity for prekallikrein and no measurable inhibitory activity against other serine proteases. The high specificity and inhibitory effect of STAR-0215 is demonstrated through a unique allosteric mechanism involving N-terminal catalytic domain binding, destabilization of the activation domain, and reversion of the active site to the inactive zymogen state. The YTE (M252Y/S254T/T256E) modified fragment crystallizable (Fc) domain of STAR-0215 enhances pH-dependent neonatal Fc receptor binding, resulting in a prolonged t_1/2 in vivo (∼34 days in cynomolgus monkeys) compared with antibodies without this modification. A single subcutaneous dose of STAR-0215 (≥100 mg) was predicted to be active in patients for 3 months or longer, based on simulations using a minimal physiologically based pharmacokinetic model. These data indicate that STAR-0215, a highly potent and specific antibody against plasma kallikrein with extended t_1/2, is a potential agent for long-term preventative HAE therapy administered every 3 months or less frequently. SIGNIFICANCE STATEMENT: STAR-0215 is a YTE-modified immunoglobulin G1 monoclonal antibody with a novel binding mechanism that specifically and potently inhibits the enzymatic activity of plasma kallikrein and prevents the generation of bradykinin. It has been designed to be a long-lasting prophylactic treatment to prevent attacks of HAE and to decrease the burden of disease and the burden of treatment for people with HAE.

130

项与 Navenibart 相关的新闻（医药）

2025-10-31

·上药睿尔

10月速览（三）罕见病药研发之投资并购

罕见病药研发之投资并购 ☞ Arbor与Chiesi达成20亿美元合作许可协议 ☞ BioCryst以9.2亿美元收购Astria ☞ 诺和诺德与Omeros达成21亿美元产品收购协议 ☞ 中外制药与Rani达成超10亿美元合作许可协议 ☞ Alkermes以21亿美元收购Avadel ☞ 诺华以120亿美元收购Avidity 01 Arbor与Chiesi达成20亿美元合作许可协议 10月6日，Arbor Biotechnologies与Chiesi Group共同宣布，双方已达成一项合作许可协议。根据协议，Chiesi Group将获得开发及商业化Arbor核心产品ABO-101的独家权利，并有权利用Arbor的基因敲除和逆转录酶编辑技术来推进其他罕见病靶点的研究。Arbor将获得高达1.15亿美元的首付款及短期款项，并有资格获得高达20亿美元的里程碑付款，以及两位数的分级特许权使用费。 ABO-101是一种靶向肝脏的一次性基因编辑疗法，旨在治疗1型原发性高草酸尿症（PH1）。ABO-101由Acuitas Therapeutics授权的脂质纳米颗粒（LNP）组成，包裹着表达新型V型CRISPR Cas12i2核酸酶的mRNA和特异性靶向人类HAO1基因的优化guide RNA，有望使肝脏中HAO1基因丧失永久性功能，从而减少与PH1相关的草酸生成。 02 BioCryst以9.2亿美元收购Astria 2025年10月14日，BioCryst Pharmaceuticals与Astria Therapeutics共同宣布，双方已达成最终收购协议，BioCryst将以“现金+股票”的方式，按每股13美元收购Astria全部股权。该交易隐含股权总价值约9.2亿美元，企业价值约7亿美元，已获双方董事会一致批准。 Astria是一家专注于开发过敏性和免疫性疾病的生命改变疗法的生物制药公司，本次收购核心标的是他的主要候选产品 Navenibart（STAR-0215），这是一款长效注射用血浆激肽释放酶抑制剂单抗，用于预防遗传性血管性水肿（HAE）发作。Navenibart的潜在最佳临床特征和每3个月和6个月的高度差异化给药计划可以显著改善现有的注射选择，并解决HAE患者社区中未满足的关键需求。 03 诺和诺德与Omeros达成21亿美元产品收购协议 2025年10月15日，诺和诺德宣布将以21亿美元从生物制药公司Omeros处购买在研罕见疾病药物扎替尼巴特（zaltenibart）的相关权利。根据协议，Omeros将获得3.4亿美元预付款，最高21亿美元的潜在开发和商业里程碑付款，以及基于净销售额的分级特许权使用费。 Zaltenibart是一款针对罕见血液及肾脏疾病的靶向补体系统关键蛋白MASP-3的单克隆抗体，可结合并抑制MASP-3，提供对替代途径活性的近端抑制。根据Omeros公布的Zaltenibart治疗阵发性睡眠性血红蛋白尿症（PNH）的II期临床试验积极数据：Zaltenibart已显示出优于其他正在研发或已上市的替代途径抑制剂的多种潜在优势，且耐受性良好。 04 中外制药与Rani达成超10亿美元合作许可协议 2025年10月17日，罗氏控股的中外制药（Chugai）宣布，其已与Rani Therapeutics达成超10亿美元合作许可协议，基于Rani的口服递送平台RaniPill开发罕见病抗体口服制剂，替代传统注射方案。根据协议，Rani将获得1000万美元的预付款，并有资格根据成功的技术转让和开发里程碑获得高达1亿美元，并在产品成功商业化后获得个位数的销售特许权使用费。此外，中外制药有权根据类似的交易条款将其权利扩展到多大5个额外的药物靶点，如果中外制药完全行使这些权利，交易总价值可能达到10.85亿美元。 Rani已签订证券购买协议，进行私募股权融资（PIPE），预计将为Rani带来约6300万美元的总收益。 05 Alkermes以21亿美元收购Avadel 2025年10月22日，Alkermes plc与Avadel Pharmaceuticals plc联合宣布，双方已达成最终收购协议。Alkermes将以每股高达20.00美元的现金总交易对价收购Avadel，交易估值约21亿美元。 Alkermes 将以每股 18.50 美元的价格收购Avadel的所有已发行普通股，并在交易结束时以现金支付。本次收购将Avadel的FDA批准产品LUMRYZ™（羟丁酸钠口服混悬液）添加到Alkermes的商业产品组合中，用于治疗7岁以上发作性睡病患者的猝倒或白天过度嗜睡，产品的核心优势是消除了夜间第二次给药的必要性，极大改善了患者依从性和生活质量。这一战略举措加快了Alkermes进入睡眠药物市场的步伐，并增强了其释放晚期开发管线全部潜力的能力，该开发管线专注于中枢性嗜睡症。截至2025年6月30日，已有约3100名患者接受了LUMRYZ™治疗，2025 年净收入预计将达到2.65亿至2.75亿美元，而美国符合羟丁酸盐治疗条件的发作性睡病患者约5万人，未来增长空间显著。 06 诺华以120亿美元收购Avidity 2025年10月26日，诺华宣布将以约120亿美元收购美国生物技术公司Avidity Biosciences，并获取该公司用于治疗罕见遗传性肌肉疾病的产品组合。诺华将获得Avidity的神经学管线和差异化技术平台，包括3个后期临床管线：杜氏肌营养不良症（DMD）的Del-zota、治疗1型强直性肌营养不良（DM1）的Del-desiran、治疗面肩肱型肌营养不良症（FSHD）的Del-brax。根据协议，诺华将通过与新成立的间接全资子公司合并，收购Avidity所有已发行普通股；在交易完成前，双方将继续作为独立公司运营。在合并完成前，Avidity 将把早期心脏病项目及相关合作转让给全资子公司SpinCo,该转让将触发其与现有合作伙伴的优先谈判权。

并购信使RNA临床2期基因疗法

2025-10-16

·药洞

Astria Therapeutics价值8亿美元的药物结构长啥样？

当地时间10月14日，BioCryst Pharmaceuticals宣布以8亿美元的价格收购Astria Therapeutics。根据协议，BioCryst将支付Astria 6亿美元的现金，以及价值2亿美元的 BioCryst 普通股。此外，如果STAR-0215达到特定的开发和商业里程碑，Astria的股东有资格获得额外的或有价值权利(CVR)。交易已获双方董事会通过，预计将于2026年第一季度完成，受收购消息推动，Astria Therapeutics股价大幅飙升37%。 Astria目前有两款产品，STAR-0215是一种潜在的同类最佳血浆激肽释放酶单克隆抗体抑制剂，旨在为遗传性血管性水肿（HAE）提供潜在的长效、安全和有效的发作预防，并可能每3个月和6个月给药一次；STAR-0310 是一种单克隆抗体OX40拮抗剂，正在开发中，用于治疗特应性皮炎（AD）的潜在药物。两者适应症和靶点均不一样，但是，两款产品同时提到了在延长给药间隙的作用。BioCryst 首席商务官Charlie Gayer在与投资者讨论这笔交易的电话会议上表示低给药频率是 HAE 患者及其医生确定的主要未满足需求。所以，今天，我们来试着找找Astria发挥这一效用的结构或者技术平台。 1、STAR-0215 STAR-0215是一种血浆激肽释放酶单克隆抗体抑制剂，检索公司专利，发现一篇关于治疗遗传性血管性水肿的抗血浆激肽释放酶抗体给药方案的专利（WO2025207078A1），专利披露的能减少使用频次的治疗HAE的单克隆抗体STAR-0215 结构，“抗体由两条重链和两条轻链组成，其中每条重链包含SEQ ID NO:9的氨基酸序列，每条轻链包含SEQ ID NO:10的氨基酸序列”。SEQ ID NO:9和SEQ ID NO:10的结构如下所示： 2、STAR-031 STAR-0310是一种单克隆抗体OX40拮抗剂，相比于传统药物治疗仅调节2型炎症，而OX40通路可调节1型、2型和3型炎症，从而实现更广泛和更深远的效果。同时，OX40配体广泛表达，而OX40受体仅限于病理性激活的T细胞，现了集中且剂量高效的靶向。STAR-0310能以大约两倍于rocatinlimab（针对OX40治疗特应性皮炎药物的单抗）的速度和效率破坏已形成的OX40/OX40L复合物。公司专利“亲和力成熟的抗OX40抗体及其用途”（WO2025076474A1）中，独立权利要求1保护了结合OX40的抗体或其抗原结合片段，其包含：a)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的三个重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：8的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)；b)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的三个重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：12的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)；c)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的三个重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：15的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)d)重链互补决定区(CDR)(CDR-H1、CDR-H2，和包含SEQ ID NO：7的氨基酸序列的重链可变结构域（VH）和三个轻链互补决定区（CDR）（CDR-L1、CDR-L2和CDR-L3）的CDR-H3）、包含SEQ ID NO：18的氨基酸序列的轻链可变结构域（VL）；e)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：21的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)；代理人案卷号。：AST-003WO f)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：24的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)；g)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：27的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)；h)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：30的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)；i)包含SEQ ID NO：7的氨基酸序列的重链可变结构域(VH)的重链互补决定区(CDR)(CDR-H1、CDR-H2和CDR-H3)和包含SEQ ID NO：33的氨基酸序列的轻链可变结构域(VL)的三个轻链互补决定区(CDR)(CDR-L1、CDR-L2和CDR-L3)。权利要求中涉及到的片段结构如下所示：同时权利要求明确了用于治疗的OX40介导的病症是关节炎、类风湿性关节炎、银屑病关节炎、哮喘、慢性阻塞性肺病(COPD)、盆腔炎性疾病、阿尔茨海默病、炎性肠病、克罗恩病、溃疡性结肠炎、佩罗尼病、乳糜泻、胆囊疾病、藏毛病、腹膜炎、银屑病、结节性痒疹；血管炎、手术粘连、中风、I型糖尿病、莱姆病、脑膜脑炎、自身免疫性葡萄膜炎、中枢和外周神经系统的免疫介导的炎性病症如多发性硬化、狼疮（如系统性红斑狼疮或狼疮性肾炎）和格林-巴尔综合征、特应性皮炎、自身免疫性肝炎、纤维化肺泡炎、格雷夫病、IgA肾病、特发性血小板减少性紫癜、梅尼埃病、天疱疮、原发性胆汁性肝硬化、结节病、硬皮病、慢性自发性荨麻疹（CSU）、慢性诱导性荨麻疹（CIU）、韦格纳肉芽肿病、胰腺炎、创伤（手术）、移植物抗宿主病（GVHD）、移植排斥、心血管血管内凝血、骨吸收、骨质疏松症、骨关节炎、牙周炎、次胃酸、化脓性汗腺炎、斑秃和视神经脊髓炎。

并购

2025-10-15

·ETPharma

BioCryst deepens rare diseases focus with $700 million deal for Astria

By Siddhi Mahatole Bengakuru: BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, strengthening its rare diseases portfolio . The offer implies a per-share value of $13, a premium of about 54% over Astria's last close. Its shares surged nearly 40%, while BioCryst fell nearly 7%. BioCryst will fund the deal, expected to close in the first quarter of 2026, with cash on hand and debt of up to $550 million raised from funds managed by Blackstone. Astria's lead drug candidate, navenibart, is being developed in a late-stage study to prevent hereditary angioedema (HAE), a rare and potentially life-threatening condition. It expects the trial data in early 2027. The long-acting injectable therapy is designed for dosing every three to six months, which could offer a more convenient alternative to existing treatments. HAE causes swelling of arms, face, legs and intestinal tract. BioCryst expects to spend less for commercialising navenibart, Chief Financial Officer Babar Ghias said as it has put in place "one of the best commercial engines in the rare disease space". While the deal uses a fair amount of BioCryst's resources, investing in a derisked HAE asset is a smarter move than backing riskier early-stage programs, said Brian Abrahams, analyst at RBC Capital Markets. BioCryst, which already markets the once-daily oral drug Orladeyo for HAE, said the acquisition would allow it to offer both oral and injectable options for the condition. It expects the HAE portfolio could drive double-digit annual revenue growth that will reach at least $1.8 billion by 2033. The company expects Orladeyo to bring in $580 million to $600 million for 2025. The drugmaker plans to seek strategic alternatives for Astria's early-stage program STAR-0310 for atopic dermatitis. Astria CEO Jill Milne will join BioCryst's board after the deal is completed. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar and Sriraj Kalluvila)

并购临床研究

100 项与 Navenibart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
I型和II型遗传性血管性水肿	临床3期	美国	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	日本	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	保加利亚	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	加拿大	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	捷克	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	德国	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	中国香港	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	以色列	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	意大利	Astria Therapeutics, Inc.	2025-03-20
I型和II型遗传性血管性水肿	临床3期	荷兰	Astria Therapeutics, Inc.	2025-03-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06007677 (ALPHA-SOLAR, PipelineReview) 人工标引	临床2期	遗传性血管性水肿	16	navenibart (600 mg / 300 mg Q3M)	壓遞憲鏇夢製鏇顧艱夢(築觸餘網網淵鹹顧顧襯) = 鹽淵糧顧製獵積範壓膚廠餘製襯築鏇齋構鏇艱 (夢製遞蓋積淵蓋鏇餘廠 ) 更多	积极	2025-06-13
				navenibart (600 mg / 600 mg at Day 28, 600 mg Q6M)	壓遞憲鏇夢製鏇顧艱夢(築觸餘網網淵鹹顧顧襯) = 鹹觸製膚觸積鑰繭廠衊廠餘製襯築鏇齋構鏇艱 (夢製遞蓋積淵蓋鏇餘廠 ) 更多
NCT05477160 (Pubmed) 人工标引	临床1期	-	41	navenibart	淵憲鹽衊襯鹹蓋築鹽顧(網鏇廠繭糧遞餘糧蓋鹹) = Rates of TEAEs were similar between navenibart and placebo, and no serious AEs were reported. Navenibart-related TEAEs included injection site reactions, inclusive of erythema, pruritus, and swelling, which resolved without intervention. 範鬱獵獵壓餘糧鑰醖範 (鹹觸鬱鏇衊鹽選糧膚選 ) 更多	积极	2025-03-01
				Placebo
NCT05695248 (ALPHA-STAR, ACAAI2024)	临床1/2期	遗传性血管性水肿 HAE-C1INH-Type1/2	16	STAR-0215 450 mg	夢遞製艱蓋襯蓋憲憲顧(鬱顧襯鑰繭淵鏇遞範糧) = 鏇膚製積繭憲鹽選鹹構鹹襯衊襯遞壓衊膚簾襯 (鹹淵鏇鏇鬱獵鹽鏇窪願, 13.4) 更多	积极	2024-10-24
				STAR-0215 600 mg	夢遞製艱蓋襯蓋憲憲顧(鬱顧襯鑰繭淵鏇遞範糧) = 網選鑰鏇製淵鬱繭網壓鹹襯衊襯遞壓衊膚簾襯 (鹹淵鏇鏇鬱獵鹽鏇窪願, 19.8) 更多
NCT05695248 (ALPHA-STAR, Biospace) 人工标引	临床1/2期	遗传性血管性水肿	16	STAR-0215 450 mg (6 months of follow-up)	積窪淵襯遞齋繭構醖艱(顧壓衊醖顧製鹽製餘餘) = 鹹積膚淵獵積範選蓋淵製餘餘醖艱獵選顧醖範 (鏇憲餘壓齋積顧鹽壓艱 ) 更多	积极	2024-03-25
				STAR-0215 600mg+300mg(three months later) (6 months of follow-up)	積窪淵襯遞齋繭構醖艱(顧壓衊醖顧製鹽製餘餘) = 鹹簾遞顧衊構淵衊選齋製餘餘醖艱獵選顧醖範 (鏇憲餘壓齋積顧鹽壓艱 ) 更多
NCT05477160 (AAAAI2024) 人工标引	临床1期	遗传性血管性水肿 cleaved high-molecular-weight-kininogen (cHMWK)	41	STAR-0215 1200 mg SC	蓋餘鏇構鏇壓獵淵繭餘(鑰廠淵糧遞顧壓鑰網願) = were seen in 10 STAR-0215 and 1 placebo subjects, most commonly injection site reactions (n=9). 襯艱簾積積醖艱構築鹹 (願構衊壓廠顧積窪淵範 ) 更多	积极	2024-02-23
NCT05695248 (ALPHA-STAR, PipelineReview) 人工标引	临床1期	遗传性血管性水肿	-	STAR-0215	壓餘壓廠餘壓選窪艱齋(顧餘構網範夢選鏇鹽觸) = STAR-0215 was well-tolerated, with no serious adverse events or discontinuations due to an adverse event, and low risk of injection pain 鹽餘糧襯蓋醖構顧淵鹹 (壓襯蓋膚醖選鹹鹹簾觸 ) 更多	积极	2023-11-10